Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade for Bone Formation in Smoldering Myeloma
NCT00983346Phase 2Terminated
- Sponsor
- University of Utah
- Start
- Oct 2009
- Primary completion
- Sep 2014
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of bortezomib in smoldering multiple myeloma (SMM), sponsored by University of Utah. Primary endpoint: Bone Anabolic Effect of Bortezomib at 6 weeks. Started Oct 2009; status: terminated.
02
Drugs
bortezomib
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT00983346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00983346.